medigraphic.com
Colegio de Medicina Interna de México.

2012, Número 5

<< Anterior Siguiente >>

Med Int Mex 2012; 28 (5)


Actualidades en la fisiopatología del síndrome de intestino irritable: el papel de las infecciones

Remes-Troche JM

Idioma: Español
Referencias bibliográficas: 74
Paginas: 461-472
Archivo PDF: 320.14 Kb.


RESUMEN

Aunque se desconoce la causa del síndrome de intestino irritable, en la actualidad se cree que esta enfermedad se origina por múltiples causas entre las que participan varios agentes que interactúan produciendo alteraciones sensitivas y motoras dentro del sistema nervioso entérico. Las infecciones, los trastornos emocionales y la dieta son algunos de los factores que más se han relacionado con estas alteraciones. La probabilidad de que las alteraciones en la flora entérica o microbiota puedan jugar un papel en la patogénesis del síndrome de intestino irritable ha comenzado a atraer la atención científica, a raíz de la descripción del síndrome de intestino irritable posinfeccioso, el papel del sobrecrecimiento bacteriano y la prescripción de antibióticos y probióticos en el tratamiento del síndrome de intestino irritable. En esta revisión se analiza la información más relevante acerca de los aspectos más novedosos de la fisiopatología del síndrome de intestino irritable y su relación con las infecciones.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. López-Colombo A, Bravo-González D, Corona-Lopez A, et al. First community-based study of functional gastrointestinal disorders (FGID) in Mexico using the modular Rome II questionnaire. Gastroenterology 2006; 130 (Suppl. 2): A508.

  2. Gralnek IM, Hays RD, Kilbourne A, et al. The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology 2000; 119:654-660.

  3. Creed F, Ratcliffe J, Fernandez L, et al. Health-related qualify of life and health care costs in severe, refractory irritable bowel syndrome. Ann Intern Med 2001; 134:860-868.

  4. Drossman DA, Camilleri M, Mayer EA, et al. AGA technical review on irritable bowel syndrome. Gastroenterology 2002; 123:2108-2131.

  5. Brandt LJ, Bjorkman D, Fennerty MB, et al. Systematic review on the management of irritable bowel syndrome in North America. Am J Gastroenterol 2002; 97:7-26.

  6. Mitchell CM, Drossman DA. Survey of the AGA membership relating to patients with functional gastrointestinal disorders. Gastroenterology 1987; 92:1282-1284.

  7. Harvey RF, Mauad EC, Brown AM. Prognosis in the irritable bowel syndrome: a five-year prospective study. Lancet 1987; 1:963-965.

  8. Talley NJ, Gabriel SE, Harmsen WS, et al. Medical costs in community subjects with irritable bowel syndrome. Gastroenterology 1995; 109:1736-1741.

  9. American Gastroenterological Association. The burden of gastrointestinal diseases. Bethesda, MD: American Gastroenterological Association, 2001.

  10. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology 2006;130:1480-91.

  11. Whitehead WE, Palsson O, Jones KR. Systematic review of the comorbidity of irritable bowel syndrome with other disorders: what are the causes and implications. Gastroenterology 2002,122:1140-56.

  12. Frissora CL, Koch KL. Symptom overlap and comorbidity of irritable bowel syndrome with other conditions. Curr Gastroenterol Reports 2005,7:264-71.

  13. Neumann H, Monkemuller K, Kandulski A, Malfertheiner P. Dyspepsia and IBS symptoms in patients with NERD, ERD and Barrett`s esophagus. Dig Dis 2008,26:243-7.

  14. Mudipalli RS, Remes-Troche JM, Andersen L, Rao SC. Functional chest pain, esophageal or overlapping functional disorder. J Clin Gastroenterol 2007;41:264.

  15. Schmulson M, Ortiz O, Santiago-Lomeli M, Gutierrez-Reyes G, Gutierrez-Ruiz MC, Robles-Diaz G, Morgan D. Frequency of functional bowel disorders among healthy volunteers in Mexico City. Dig Dis 2006;24:342-7.

  16. Valerio-Ureña J, Pérez-Sosa JA, Jiménez Pineda A, Cortázar- Benítez LF, Duarte-Velázquez ME, Prieto-Murguía EG y cols. Prevalencia del síndrome de intestino irritable en población abierta de la ciudad de Veracruz. Rev Gastroenterol Méx 2006;71 (Suppl 2):124.

  17. Hawrelak JA, Mayer SP. The causes of intestinal dysbiosis: a review. Altern Med Rev 2004, 9: 180-197.

  18. Mendall MA, Kumar D. Antibiotic use, childhood affluence and irritable bowel syndrome (IBS). Eur J Gastroenterol Hepatol 1998; 10:59-62.

  19. McKendrick MW, Read MW. Irritable bowel syndrome-postsalmonella infection. J Infect 1994; 29:1-3.

  20. Thabane M, Kottachchi DT, Marshall JK. Systematic review and meta-analysis: the incidence and prognosis of post-infectious irritable bowel syndrome. Aliment Pharmacol Therp 2007; 26:535-544.

  21. Marshall JK, Thabane M, Garg AX, Clark WF, Salvadori M, Collins SM; Walkerton Health Study Investigators. Incidence and epidemiology of irritable bowel syndrome after a large waterborne outbreak of bacterial dysentery. Gastroenterology 2006 ;131(2):445-450.

  22. Marshall JK, Thabane M, Garg AX, Clark WF, Moayyedi P, Collins SM; Walkerton Health Study Investigators. Eight year prognosis of postinfectious irritable bowel syndrome following waterborne bacterial dysentery. Gut. 2010 ;59(5):605-611.

  23. Villani AC, Lemire M, Thabane M, Belisle A, Geneau G, Garg AX, Clark WF, Moayyedi P, Collins SM, Franchimont D, Marshall JK. Genetic risk factors for post-infectious irritable bowel syndrome following a waterborne outbreak of gastroenteritis. Gastroenterology 2010;138(4):1502-1513.

  24. Marshall JK, Thabane M, Borgaonkar MR, James C. Postinfectious irritable bowel syndrome after a food-borne outbreak of acute gastroenteritis attributed to a viral pathogen. Clin Gastroenterol Hepatol 2007;5(4):457-460.

  25. Wensaas KA, Langeland N, Hanevik K, Mørch K, Eide GE, Rortveit G. Irritable bowel syndrome and chronic fatigue 3 years after acute giardiasis: historic cohort study. Gut 2012;61(2):214-219.

  26. Gwee KA; Leong YI, Graham C et al. The role of psychological and biological factors in post-infective gut dysfunction. Gut 1999; 44: 400-06.

  27. Borgaonkar MR, Ford DC, Marshall JK, Churchill E, Collins SM. The incidence of irritable bowel syndrome among community subjects with previous acute enteric infection. Dig Dis Sci 2006; 51: 1026-32.

  28. Chadwick V, Chen W, Shu D, et al. Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology 2002; 122: 1778-83.

  29. Collins SM. A case for an immunological basis for irritable bowel syndrome. Gastroenterology 2002; 122: 2078-80.

  30. Spiller RC. Role of nerves in enteric infection. Gut 2002; 51:759-62.

  31. Bradley HK, Wyatt GM, Bayliss CE, Hunter JO. Instability in the faecal flora of a patient suffering from food-related irritable bowel syndrome. J Med Microbiol 1987; 23: 29-32.

  32. Dear KL, Elia M, Hunter JO. Do interventions which reduce colonic bacterial fermentation improve symptoms of irritable bowel syndrome? Dig Dis Sci 2005; 50: 758.66.

  33. King TS, Elia M, Hunter JO. Abnormal colonic fermentation in irritable bowel syndrome. Lancet 1998; 352: 1187-9.

  34. Pimentel M, Chow EJ, Lin HC. Eradication of small bowel bacterial overgrowth reduces symptom of irritable bowel syndrome. Am J Gastroenterol 2000; 95: 3503-6.

  35. Pimentel M, Chow E, Lin HC. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome: a double-blind randomizaed, placebo-controlled study. Am J Gastroenterol 2003; 98: 412-9.

  36. Pimentel M, Soffer EE, Chow EJ, Kong Y, Lin HC. Lower frequency of MMC is found in IBS subjects with abnormal lactulose breath test, suggesting bacterial overgrowth. Dig Dis Sci 2002;47:2639-2643.

  37. Pimentel M, Park S, Mirocha J, Kane SV, Kong Y. The effect of a nonabsorbed antibiotic (rifaximin) on the symptoms of irritable bowel syndrome: a randomized trial. Ann Intern Med 2006; 145:557-563.

  38. Posserud I, Stotzer PO, Björnsson ES, Abrahamsson H, Simrén M. Small intestinal bacterial overgrowth in patients with irritable bowel syndrome. Gut. 2007;5 6(6):802-8.

  39. Pimentel M, Lembo A, Chey WD, Zakko S, Ringel Y, Yu J, Mareya SM, Shaw AL, Bortey E, Forbes WP; TARGET Study Group. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med 2011;6364(1):22-32.

  40. Menees SB, Maneerattannaporn M, Kim HM, Chey WD. The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis. Am J Gastroenterol 2012;107(1):28-35.

  41. Pimentel M, Morales W, Chua K, Barlow G, Weitsman S, Kim G, Amichai MM, Pokkunuri V, Rook E, Mathur R, Marsh Z. Effects of rifaximin treatment and retreatment in nonconstipated IBS subjects. Dig Dis Sci 2011; 56(7):2067-72.

  42. Robins GW, Wellington K. Rifaximin: a review of its use in the management of traveller's diarrhoea. Drugs. 2005;65(12):1697- 713.

  43. Cremonini F, Lembo A. Rifaximin for the treatment of irritable bowel syndrome. Expert Opin Pharmacother 2012;13(3):433- 40.

  44. Frissora CL, Cash BD. Review article: the role of antibiotics vs. conventional pharmacotherapy in treating symptoms of irritable bowel syndrome. Aliment Pharmacol Ther 2007;25:1271-81.

  45. Fumi A, Katherine T. Rifaximin treatment for symptoms of irritable bowel syndrome. Ann Pharmacother 2008;42:408-12.

  46. Jiang ZD, Ke S, Palazzini E, Riopel L, Dupont H. In vitro activity and fecal concentration of rifaximin after oral administration. Antimicrob Agents Chemother 2000;44:2205-6.

  47. Sharara AI, Aoun E, Abdul-Baki H, Mounzer R, Sidani S, Elhajj I. A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence. Am J Gastroenterol 2006;101:326-33.

  48. Schrezenemeir J, de Vrese M. Prebiotics, probiotics, and synbiotics approaching a definition. Am J Clin Nutr 2001;73:361S– 4S.

  49. Spiller R. Review article: probiotics and prebiotics in irritable bowel syndrome. Aliment Pharmacol Ther 2008;28:385-96.

  50. Gibson GR, Roberfroid MB. Dietary modulation of the human colonic micro- biota: introducing the concept of prebiotics. J Nutr 1995;125:1401–1.

  51. Roberfroid M. Prebiotics the concept revisited . J Nutr 2007;137:830S–7S.

  52. Adler SN. The probiotic agent Escherichia coli M-17 has a healing effect in patients ith IBS ith proximal inflammation of the small bowel. Dig Liver Dis 2006;38:713.

  53. Bazzocchi G, Gionchetti P, Almerigi PF, Amadini C, Campieri M. Intestinal microflora and oral bacteriotherapy in irritable bowel syndrome. Dig Liver Dis 2002;34(suppl 2): S48-S53.

  54. Garonska A, Dziechciarz P, Horvath A, Szajeska H. A randomized double- blind placebo-controlled trial of Lactobacillus GG for abdominal pain disorders in children. Aliment Pharmacol Ther 2007;25:177–84.

  55. O’Mahony L, McCarthy J, Kelly P, et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005;128:541–51.

  56. Bausserman M, Michail S. The use of Lactobacillus GG in irritable bowel syndrome in children: a double-blind randomized control trial. J Pediatr 2005;147:197–201.

  57. Sen S, Mullan MM, Parker TJ, Woolner JT, Tarry SA, Hunter JO. Effect of Lac- tobacillus plantarum 299 v on colonic fermentation and symptoms of irritable bowel syndrome. Dig Dis Sci 2002;47:2615–20.

  58. O’Sullivan MA, OMorain CA. Bacterial supplementation in the irritable bowel syndrome. A randomized doubleblind placebo-controlled crossover study. Dig Liver Dis 2000;32:294–301.

  59. Niv E, Naftali T, Hallak R, Vaisman N. The efficacy of Lactobacillus reuteri ATCC 55730 in the treatment of patients ith irritable bowel syndrome: a double-blind, placebo-controlled, randomized study. Clin Nutr 2005;24:925–31.

  60. Nifkar S, Rahimi R, Rahimi F, et al. Efficacy of probiotics in irritable bowel syndrome: A meta-analysis of randomized, controlled trials. Dis Col Rect 2008;51:1775-80.

  61. Sinn DH, Song JH, Kim HJ, et al. Therapeutic effect of Lactobacillus acidophilus-SDC 2012, 2013 in patients with irritable bowel syndrome. Dig Dis Sci 2008;53:2714-2718.

  62. Niedzielin K, Kordecki H, Birkenfeld B. A controlled, doubleblind, randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome. Eur J Gastroenterol Hepatol 2001;13:1143-1147.

  63. Nobaek S, Johansson ML, Molin G, Ahrné S, Jeppsson B. Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Am J nGastroenterol 2000;95:1231-1238

  64. Whorwell PJ, Altringer L, Morel J, et al. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol 2006;101:1581- 1590.

  65. Guyonnet D, Chassany O, Ducrotte P, et al. Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double-blind, controlled trial. Aliment Pharmacol Ther 2007;26:475- 486.

  66. Enck P, Zimmermann K, Menke G, Klosterhalfen S. Randomized controlled treatment trial of irritable bowel syndrome with a probiotic E. coli preparation (DSM17252) compared to placebo. Z Gastroenterol 2009;47:209-214.

  67. Kim HJ, Camilleri M, McKinzie S, et al. A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2003;17:895-904.

  68. Kim HJ, Vazquez Roque MI, Camilleri M, et al. A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating. Neurogastroenterol Motil 2005;17:687-696.

  69. Kajander K, Myllyluoma E, Rajilić-Stojanović M, et al. Clinical trial: multispecies probiotic supplementation alleviates the symptoms of irritable bowel syndrome and stabilizes intestinal microbiota. Aliment Pharmacol Ther 2008;27:48-57.

  70. Kajander K, Hatakka K, Poussa T, Färkkilä M, Korpela R. A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: a controlled 6-month intervention. Aliment Pharmacol Ther 2005;22:387-394.

  71. Williams EA, Stimpson J, Wang D, et al. Clinical trial: a multistrain probiotic preparation significantly reduces symptoms of irritable bowel syndrome in a double-blind placebo-controlled study. Aliment Pharmacol Ther 2009;29:97-103.

  72. Tsuchiya J, Barreto R, Okura R, Kawakita S, Fesce E, Marotta F. Single-blind follow-up study on the effectiveness of a symbiotic preparation in irritable bowel syndrome. Chin J Dig Dis 2004; 5:169-174.

  73. Drouault-Holowacz S, Bieuvelet S, Burckel A, Cazaubiel M, Dray X, Marteau P. A double blind randomized controlled trial of a probiotic combination in 100 patients with irritable bowel syndrome. Gastroenterol Clin Biol 2008;32:147-152.

  74. Hong KS, Kang HW, Im JP, et al. Effect of probiotics on symptoms in Korean adults with irritable bowel syndrome. Gut Liver 2009;3:101-107.




2020     |     www.medigraphic.com